Ginkgo bioworks reports third quarter 2024 financial results

Ginkgo provides update on its restructuring process including an acceleration of site consolidation initiatives and continued progress on cost reductions ginkgo signs new and expanded deals with novo nordisk and achieves a major research milestone with merck  boston , nov. 12, 2024 /prnewswire/ -- ginkgo bioworks holdings, inc. (nyse: dna, "ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced its results for the third quarter ended september 30, 2024. the update, including a webcast slide presentation with additional details on the third quarter and supplemental financial information will be available at investors.ginkgobioworks.com.
DNA Ratings Summary
DNA Quant Ranking